Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with Hereditary Angioedema Type I or II

Next Previous
Trial Profile

Open-Label Safety, Pharmacokinetic, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) with Hereditary Angioedema Type I or II

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 12 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sebetralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Adverse reactions
  • Acronyms KONFIDENT-KID
  • Sponsors KalVista Pharmaceuticals

Most Recent Events

  • 22 May 2025 According to a KalVista Pharmaceuticals media release, results data from this trial, selected for oral presentation at Eastern Allergy Conference (EAC) in Palm Beach, Florida, which will take place during Scientific Session V on Sat, May 31.
  • 22 May 2025 According to a KalVista Pharmaceuticals media release, new sebetralstat data from this trial, selected for oral presentation, taking place concurrently from May 29-June 1, 2025: the 14th C1-inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary, during Scientific Session V on Sat, May 31.
  • 02 Apr 2025 Planned number of patients changed from 24 to 36.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top